Loading...
JANX logo

Janux Therapeutics, Inc.NasdaqGM:JANX Stock Report

Market Cap US$878.2m
Share Price
US$14.41
US$40.56
64.5% undervalued intrinsic discount
1Y-42.8%
7D0.1%
1D
Portfolio Value
​
View

Janux Therapeutics, Inc.

NasdaqGM:JANX Stock Report

Market Cap: US$878.2m

Janux Therapeutics (JANX) Stock Overview

A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. More details

JANX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 45.12% per year

Risk Analysis

Earnings are forecast to decline by an average of 19.3% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years


JANX Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Janux Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Janux Therapeutics
Historical stock prices
Current Share PriceUS$14.41
52 Week HighUS$35.34
52 Week LowUS$12.12
Beta2.57
1 Month Change-6.79%
3 Month Change10.17%
1 Year Change-42.84%
3 Year Change25.74%
5 Year Changen/a
Change since IPO-42.70%

Recent News & Updates

Analysis Article • May 13

Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts

Celebrations may be in order for Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders, with the analysts delivering a...
Analysis Article • May 11

Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Janux Therapeutics, Inc. ( NASDAQ:JANX ) came out with its quarterly results last week, and we wanted to see how the...
Seeking Alpha • May 04

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Summary Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation. Despite early-stage pipeline risks and near-term volatility, JANX’s cash position and platform progress justify a high-risk, long-term investment thesis. Read the full article on Seeking Alpha

Recent updates

Analysis Article • May 13

Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts

Celebrations may be in order for Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders, with the analysts delivering a...
Analysis Article • May 11

Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Janux Therapeutics, Inc. ( NASDAQ:JANX ) came out with its quarterly results last week, and we wanted to see how the...
Seeking Alpha • May 04

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Summary Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation. Despite early-stage pipeline risks and near-term volatility, JANX’s cash position and platform progress justify a high-risk, long-term investment thesis. Read the full article on Seeking Alpha
Analysis Article • Oct 08

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Apr 23

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Dec 03

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Summary Janux Therapeutics' TRACTr platform shows promise with encouraging early data, but the high valuation for a phase 1 company makes it a risky investment. The PSMA-targeted JANX007 has shown significant PSA reductions and partial tumor responses, but long-term efficacy and safety remain uncertain. JANX has a strong cash position, reducing immediate financial risks, but the market's high expectations could lead to severe valuation drops if data disappoints. Despite potential buyout rumors, the unproven nature of JANX's technology and the high market cap lead me to maintain a “Strong Sell” rating. Read the full article on Seeking Alpha
Analysis Article • Oct 01

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 01

Janux Therapeutics: Buoyed By Buyout Speculation

Summary Today, we take another look at clinical stage biotech concern Janux Therapeutics, whose stock has soared in 2024. The shares have been buoyed throughout most of 2024 by a bevy of buyout speculation and some promising early-stage trial data. The company has a robust balance sheet and is targeting some potentially large markets. However, the company's pipeline is early-stage and there was some significant insider selling in the stock in early June at near all-time highs. Can the rally in Janux Therapeutics continue? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Jul 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 11

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Summary Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes. I recommend a cautious 'Buy' for JANX, highlighting its speculative nature, potential risks in drug development, and competition in the mCRPC market. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Summary Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032. Positive preliminary data also observed for the other phase 1a study using JANX008 for the treatment of patients with EGFR expressing solid tumors. Read the full article on Seeking Alpha
Analysis Article • Feb 24

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Dec 29

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Key Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Nov 04

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jul 20

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 23

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Insights The projected fair value for Janux Therapeutics is US$15.07 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Feb 09

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Oct 19

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 09

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics press release (NASDAQ:JANX): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022
Analysis Article • Jun 05

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 19

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Nov 03

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

JANXUS BiotechsUS Market
7D0.1%-1.6%-0.8%
1Y-42.8%34.4%27.1%

Return vs Industry: JANX underperformed the US Biotechs industry which returned 32.9% over the past year.

Return vs Market: JANX underperformed the US Market which returned 26.7% over the past year.

Price Volatility

Is JANX's price volatile compared to industry and market?
JANX volatility
JANX Average Weekly Movement5.1%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: JANX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: JANX's weekly volatility has decreased from 11% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017108David Campbellwww.januxrx.com

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases.

Janux Therapeutics, Inc. Fundamentals Summary

How do Janux Therapeutics's earnings and revenue compare to its market cap?
JANX fundamental statistics
Market capUS$878.17m
Earnings (TTM)-US$114.48m
Revenue (TTM)US$13.73m
64.0x
P/S Ratio
-7.7x
P/E Ratio

Is JANX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JANX income statement (TTM)
RevenueUS$13.73m
Cost of RevenueUS$127.65m
Gross Profit-US$113.92m
Other ExpensesUS$557.00k
Earnings-US$114.48m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.88
Gross Margin-829.54%
Net Profit Margin-833.60%
Debt/Equity Ratio0%

How did JANX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 23:59
End of Day Share Price 2026/05/21 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Janux Therapeutics, Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Alec StranahanBofA Global Research
Suranjit MukherjeeBTIG